Charge-Stablized Nanostructure Technology

Revalesio is developing a novel category of therapeutics for the treatment of inflammatory diseases using its proprietary charge-stabilized nanostructure (CSN) technology. Revalesio’s products are created using a patented device that generates rotational forces, cavitation, and high-energy fluid dynamics to create unique, stable nanostructures in liquids. CSNs are less than 100 nanometers in size (for reference, the width of a single strand of hair is 100,000 nanometers) and consist of a stabilized nano-sized oxygen bubble core.

RNS60

RNS60 is Revalesio’s lead product candidate based upon CSN technology. RNS60 is generated by processing normal, medical-grade, isotonic saline with Revalesio’s technology. RNS60 offers a unique and groundbreaking approach to treating diseases through a combination of three key features:

  • Efficacy – Pre-clinical and clinical research has demonstrated RNS60 has significant anti-inflammatory and cytoprotective activity in multiple diseases.
  • Safety – RNS60 has demonstrated an excellent safety profile in multiple pre-clinical toxicology studies and clinical trials.
  • Novel Mechanism of Action – CSN technology represents a new category of therapeutics that utilize a novel approach to alter cellular signaling in response to stress without crippling normal cell function.

rns60-diagram

MECHANISM OF ACTION

In contrast to traditional therapies such as biologics and some small molecules, RNS60 was not designed to target a single cellular protein. Instead, RNS60 utilizes CSNs to disrupt inflammatory signals to prevent a cascade of biochemical events that cause cell and tissue damage. RNS60 modulates the PI3K-Akt pathway, a central pathway responsible for multiple cellular functions including cellular protection from death (apoptosis) and the reduction of inflammation. In addition, RNS60 exerts a positive impact on mitochondria and bioenergetics. In summary, therapeutics containing CSNs represent a novel approach to protect cells exposed to stressful conditions and thereby prevent and treat inflammatory diseases.


Applications

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean vitae nulla volutpat, ullamcorper est a, ullamcorper nunc. In tincidunt erat et felis interdum ornare in nec enim. Donec sed turpis sit amet velit sagittis dictum id eget enim. Sed varius urna non aliquet ultricies. Vivamus in ex pretium, finibus velit eget, semper velit. Proin at porttitor sapien. Aenean nec volutpat sapien, eu vehicula mauris. Sed in varius erat. Quisque quis ullamcorper nulla. Aliquam et justo eu augue commodo commodo id quis magna. Duis ac ultrices diam.

TITLE HERE

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean vitae nulla volutpat, ullamcorper est a, ullamcorper nunc. In tincidunt erat et felis interdum ornare in nec enim. Donec sed turpis sit amet velit sagittis dictum id eget enim. Sed varius urna non aliquet ultricies. Vivamus in ex pretium, finibus velit eget, semper velit. Proin at porttitor sapien. Aenean nec volutpat sapien, eu vehicula mauris. Sed in varius erat. Quisque quis ullamcorper nulla. Aliquam et justo eu augue commodo commodo id quis magna. Duis ac ultrices diam.

  • Sed in varius erat. Quisque quis ullamcorper nulla. Aliquam et justo eu augue commodo commodo id quis magna. Duis ac ultrices diam.
  • Sed in varius erat. Quisque quis ullamcorper nulla. Aliquam et justo eu augue commodo commodo id quis magna. Duis ac ultrices diam.
  • Sed in varius erat. Quisque quis ullamcorper nulla. Aliquam et justo eu augue commodo commodo id quis magna. Duis ac ultrices diam.

Sed in varius erat. Quisque quis ullamcorper nulla. Aliquam et justo eu augue commodo commodo id quis magna. Duis ac ultrices diam.

 

TITLE HERE

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean vitae nulla volutpat, ullamcorper est a, ullamcorper nunc. In tincidunt erat et felis interdum ornare in nec enim. Donec sed turpis sit amet velit sagittis dictum id eget enim. Sed varius urna non aliquet ultricies. Vivamus in ex pretium, finibus velit eget, semper velit. Proin at porttitor sapien. Aenean nec volutpat sapien, eu vehicula mauris. Sed in varius erat. Quisque quis ullamcorper nulla. Aliquam et justo eu augue commodo commodo id quis magna. Duis ac ultrices diam.


Mitochondrial Health

Revalesio is developing a novel category of therapeutics for the treatment of inflammatory diseases using its proprietary charge-stabilized nanostructure (CSN) technology. Revalesio’s products are created using a patented device that generates rotational forces, cavitation, and high-energy fluid dynamics to create unique, stable nanostructures in liquids. CSNs are less than 100 nanometers in size (for reference, the width of a single strand of hair is 100,000 nanometers) and consist of a stabilized nano-sized oxygen bubble core.

RNS60

RNS60 is Revalesio’s lead product candidate based upon CSN technology. RNS60 is generated by processing normal, medical-grade, isotonic saline with Revalesio’s technology. RNS60 offers a unique and groundbreaking approach to treating diseases through a combination of three key features:

  • Efficacy – Pre-clinical and clinical research has demonstrated RNS60 has significant anti-inflammatory and cytoprotective activity in multiple diseases.
  • Safety – RNS60 is remarkably safe. It has demonstrated an excellent safety profile in multiple pre-clinical toxicology studies and has successfully complete three clinical safety studies without any concerns for safety or tolerability.
  • Novel Mechanism of Action – CSN technology represents a new category of therapeutics that utilize a novel approach to alter cellular signaling in response to stress without crippling normal cell function.

Presently, RNS60 is in clinical development for Asthma, Multiple Sclerosis, Alzheimer’s disease, and Parkinson’s disease.

rns60-diagram

 

MECHANISM OF ACTION

In contrast to traditional therapies such as biologics and some small molecules, RNS60 was not designed to target a single cellular protein. Instead, RNS60 utilizes CSNs to disrupt inflammatory signals at the cell membrane and to prevent a cascade of biochemical events that cause cell and tissue damage. RNS60 modulates the PI3K-Akt pathway, a central pathway responsible for multiple cellular functions including cellular protection from death (apoptosis) and the reduction of inflammation. In addition, RNS60 exerts a positive impact on mitochondria and bioenergetics. In summary, therapeutics containing CSNs represent a novel approach to protect cells exposed to stressful conditions and thereby prevent and treat inflammatory diseases.

Visit our programs to learn more about applications for our technology.


Biology

Revalesio is developing a novel category of therapeutics for the treatment of inflammatory diseases using its proprietary charge-stabilized nanostructure (CSN) technology. Revalesio’s products are created using a patented device that generates rotational forces, cavitation, and high-energy fluid dynamics to create unique, stable nanostructures in liquids. CSNs are less than 100 nanometers in size (for reference, the width of a single strand of hair is 100,000 nanometers) and consist of a stabilized nano-sized oxygen bubble core.

RNS60

RNS60 is Revalesio’s lead product candidate based upon CSN technology. RNS60 is generated by processing normal, medical-grade, isotonic saline with Revalesio’s technology. RNS60 offers a unique and groundbreaking approach to treating diseases through a combination of three key features:

  • Efficacy – Pre-clinical and clinical research has demonstrated RNS60 has significant anti-inflammatory and cytoprotective activity in multiple diseases.
  • Safety – RNS60 is remarkably safe. It has demonstrated an excellent safety profile in multiple pre-clinical toxicology studies and has successfully complete three clinical safety studies without any concerns for safety or tolerability.
  • Novel Mechanism of Action – CSN technology represents a new category of therapeutics that utilize a novel approach to alter cellular signaling in response to stress without crippling normal cell function.

Presently, RNS60 is in clinical development for Asthma, Multiple Sclerosis, Alzheimer’s disease, and Parkinson’s disease.

rns60-diagram

MECHANISM OF ACTION

In contrast to traditional therapies such as biologics and some small molecules, RNS60 was not designed to target a single cellular protein. Instead, RNS60 utilizes CSNs to disrupt inflammatory signals at the cell membrane and to prevent a cascade of biochemical events that cause cell and tissue damage. RNS60 modulates the PI3K-Akt pathway, a central pathway responsible for multiple cellular functions including cellular protection from death (apoptosis) and the reduction of inflammation. In addition, RNS60 exerts a positive impact on mitochondria and bioenergetics. In summary, therapeutics containing CSNs represent a novel approach to protect cells exposed to stressful conditions and thereby prevent and treat inflammatory diseases.

Visit our programs to learn more about applications for our technology.


Physics

Revalesio is developing a novel category of therapeutics for the treatment of inflammatory diseases using its proprietary charge-stabilized nanostructure (CSN) technology. Revalesio’s products are created using a patented device that generates rotational forces, cavitation, and high-energy fluid dynamics to create unique, stable nanostructures in liquids. CSNs are less than 100 nanometers in size (for reference, the width of a single strand of hair is 100,000 nanometers) and consist of a stabilized nano-sized oxygen bubble core.

RNS60

RNS60 is Revalesio’s lead product candidate based upon CSN technology. RNS60 is generated by processing normal, medical-grade, isotonic saline with Revalesio’s technology. RNS60 offers a unique and groundbreaking approach to treating diseases through a combination of three key features:

  • Efficacy – Pre-clinical and clinical research has demonstrated RNS60 has significant anti-inflammatory and cytoprotective activity in multiple diseases.
  • Safety – RNS60 is remarkably safe. It has demonstrated an excellent safety profile in multiple pre-clinical toxicology studies and has successfully complete three clinical safety studies without any concerns for safety or tolerability.
  • Novel Mechanism of Action – CSN technology represents a new category of therapeutics that utilize a novel approach to alter cellular signaling in response to stress without crippling normal cell function.

Presently, RNS60 is in clinical development for Asthma, Multiple Sclerosis, Alzheimer’s disease, and Parkinson’s disease.

rns60-diagram

MECHANISM OF ACTION

In contrast to traditional therapies such as biologics and some small molecules, RNS60 was not designed to target a single cellular protein. Instead, RNS60 utilizes CSNs to disrupt inflammatory signals at the cell membrane and to prevent a cascade of biochemical events that cause cell and tissue damage. RNS60 modulates the PI3K-Akt pathway, a central pathway responsible for multiple cellular functions including cellular protection from death (apoptosis) and the reduction of inflammation. In addition, RNS60 exerts a positive impact on mitochondria and bioenergetics. In summary, therapeutics containing CSNs represent a novel approach to protect cells exposed to stressful conditions and thereby prevent and treat inflammatory diseases.

Visit our programs to learn more about applications for our technology.


Clinical Trials

Revalesio’s technology and its lead therapeutic product, RNS60, have been reviewed in numerous scientific journals and is being investigated in preclinical and clinical trials around the world. Revalesio does not make recommendations regarding individuals in clinical trials. If you are interested in participating in a clinical trial please visit the clinicaltrials.gov website and/or discuss with your personal physician.